Let me re-phrase, they have no current operations and revenue from MEDICINAL hemp products.
They have primary market and operations in hemp food products, but the medicinal oil is still in r&d.
With a 20m raise, consequently increasing market cap, is a revenue stream from hemp food products worth the 60-70% premium at which traders got in at?
Dont get me wrong, i'm one of the lucky few that got 80k+ and no doubt EXL has a good business model, but how long til the primary product goes into production?
And is a stock in R&D worth your 60-70% premium?
DYOR, GLTAH
IPO - Elixinol Global Limited, page-49
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EXL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.002(33.3%) |
Mkt cap ! $6.605M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $2.103K | 475.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 7670493 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 924824 | 4 |
View Market Depth
| Last trade - 14.04pm 29/11/2024 (20 minute delay) ? |
| EXL (ASX) Chart |
Day chart unavailable
